| Filed On | Filing |
|---|---|
| 27 Oct 2026 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, October 27, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2026. |
| 11 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Nautilus Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: |
| 28 Jul 2026 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026. |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Nautilus Biotechnology, Inc. (the “Company”) held its 2026 annual meeting of stockholders on June 17, 2026 (the “Annual Meeting”). Of the 127,078,855 shares of the Company’s common stock outstanding as of the record date of April 20, 202... |
| 28 Apr 2026 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, April 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, February 26, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2... |
| 04 Nov 2025 |
8-K: Other Events
On November 3, 2025, Nautilus Biotechnology, Inc. (the “Company”) received a written notice from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained complian... |
| 28 Oct 2025 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, October 28, 2025 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025. |
| 31 Jul 2025 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, July 31, 2025 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025. |
| 23 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Nautilus Biotechnology, Inc. (the “Company”) held its 2025 annual meeting of stockholders on June 20, 2025 (the “Annual Meeting”). Of the 126,148,469 shares of the Company’s common stock outstanding as of the record date of April 22, 202... |
| 02 May 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On May 1st, 2025, Nautilus Biotechnology, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of... |
| 29 Apr 2025 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, April 29, 2025 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
SEATTLE, WA, February 27, 2025 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended... |
| 31 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 an... |
| 29 Oct 2024 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, October 29, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024. |
| 30 Jul 2024 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, July 30, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. |
| 13 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
Nautilus Biotechnology, Inc. (the “Company”) held its 2024 annual meeting of stockholders on June 13, 2024 (the “Annual Meeting”). Of the 125,265,015 shares of the Company’s common stock outstanding as of the record date of April 16, 202... |
| 30 Apr 2024 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, April 30, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. |
| 28 Feb 2024 |
8-K: Entry into a Material Definitive Agreement
Nautilus Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“TD Cowen”), as follows: |
| 28 Feb 2024 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, February 28, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended... |
Loading...